ResMed posts Q1 FY27 beat with $1.4 B revenue, $2.91 EPS and $1 B returned to shareholders
ResMed reported fiscal Q1 2027 revenue of $1.4 billion, up 6% year‑over‑year and 7% on a core constant‑currency basis. Non‑GAAP earnings per share were $2.91, a 14% increase, and the company returned more than $1 billion to shareholders through buybacks and dividends. Management kept FY27 guidance of $5.75‑$5.85 billion revenue and $12‑$12.25 EPS, while noting near‑term margin pressure and a back‑half headwind from France fleet renewal.
Why it matters
The earnings beat and strong cash return support the current FY27 guidance, so investors can expect the same revenue and EPS targets to remain in place. However, the noted margin pressure and upcoming fleet‑renewal headwinds may affect profitability in the second half of the year.
Key facts
- 1Revenue was $1.4 billion, up 6% year‑over‑year. investing.com
- 2Revenue grew 7% on a core constant‑currency basis. investing.com
- 3Non‑GAAP EPS was $2.91. investing.com
- 4Non‑GAAP gross margin was 62.5%. investing.com
- 5The company returned more than $1 billion to shareholders via buybacks and dividends. investing.com
- 6Free cash flow for the quarter was $374 million. finance.yahoo.com
Summary written by AlphAI AI Desk from 14 of 14 sources. Not investment advice. Figures are as stated by the linked sources.